A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma

Human Gene Therapy

Volumn 24, Issue 5, 2013, Pages 554-564

  Lange, Sebastian ^a   Lampe, Johanna ^a,c   Bossow, Sascha ^b,d   Zimmermann, Martina ^a   Neubert, Wolfgang ^b   Bitzer, Michael ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c Institute for Molecular Medicine Finland   (Finland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUOROURIDINE MONOPHOSPHATE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; FLUOROURIDINE; HYBRID PROTEIN; MEASLES VACCINE VIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; SUPER CYTOSINE DEAMINASE; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER SURVIVAL; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TRANSGENE; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION;

ANIMALS; BILE DUCT NEOPLASMS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FLUOROURACIL; GENETIC THERAPY; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84877844935     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.136     Document Type: Article

References (47)

1. Akamatsu, N., Sugawara, Y., and Hashimoto, D. (2011). Surgical strategy for bile duct cancer: advances and current limitations. World J. Clin. Oncol. 2, 94-107.
2. Anderson, B.D., Nakamura, T., Russell, S.J., and Peng, K.W. (2004). High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer. Res. 64, 4919-4926.
3. Blechacz, B.R.A., and Gores, G.J. (2008). Cholangiocarcinoma. Clin. Liver Dis. 12, 131-150, ix.
4. Bossow, S., Grossardt, C., Temme, A., et al. (2011). Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther. 18, 598-608.
5. Buchholz, U.J., Finke, S., and Conzelmann, K.K. (1999). Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259.
6. Cattaneo, R., Rebmann, G., Schmid, A., et al. (1987). Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J. 6, 681-688.
7. Cattaneo, R., Miest, T., Shashkova, E.V., and Barry, M.A. (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6, 529-540.
8. Deng, L.-Y., Wang, J.-P., Gui, Z.-F., and Shen, L.-Z. (2011). Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. World J. Gastroenterol. 17, 2958-2964.
9. Dingli, D., Peng, K.W., Harvey, M.E., et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide sym-porter. Blood 103, 1641-1646.
10. Enjoji, M., Sakai, H., Nawata, et al. (1997). Sarcomatous and adenocarcinoma cell lines from the same nodule of cho-langiocarcinoma. In Vitro Cell Dev. Biol. Anim. 33, 681-683.
11. Erbs, P., Regulier, E., Kintz, J., et al. (2000). In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60, 3813-3822.
12. Erbs, P., Findeli, A., Kintz, J., et al. (2008). Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 15, 18-28.
13. Galanis, E., Hartmann, L.C., Cliby, W.A., et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875-882.
14. Graepler, F., Lemken, M.-L., Wybranietz, W.A., et al. (2005). Bi-functional chimeric SuperCD suicide gene-YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J. Gastroenterol. 11, 6910-6919.
15. Griffin, D.E., Pan, C.-H., and Moss, W.J. (2008). Measles vaccines. Front. Biosci. 13, 1352-1370.
16. Jarnagin, W.R., Zager, J.S., Hezel, M., et al. (2006). Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 13, 326-334.
17. Jemal, A., Bray, F., Center, M.M., et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
18. Kärber, G. (1931). Beitrag zur kollektiven Behandlung pharma-kologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162, 480-483.
19. Kojima, Y., Honda, K., Hamada, H., and Kobayashi, N. (2009). Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J. Surg. Res. 157, e63-e70.
20. Lech, P.J., and Russell, S.J. (2010). Use of attenuated para-myxoviruses for cancer therapy. Expert Rev. Vaccines 9, 1275-1302.
21. Liu, T.-C., and Kirn, D. (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15, 877-884.
22. Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338.
23. Miyagiwa, M., Ichida, T., Tokiwa, T., et al. (1989). A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev. Biol. 25, 503-510.
24. Mosconi, S., Beretta, G.D., Labianca, R., et al. (2009). Cho-langiocarcinoma. Crit. Rev. Oncol. Hematol. 69, 259-270.
25. Msaouel, P., Dispenzieri, A., and Galanis, E. (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr. Opin. Mol. Ther. 11, 43-53.
26. Patel, T. (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepa-tology 33, 1353-1357.
27. Pederson, L.C., Buchsbaum, D.J., Vickers, S.M., et al. (1997). Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57, 4325-4332.
28. Peng, K.-W., Facteau, S., Wegman, T., et al. (2002). Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8, 527-531.
29. Russell, S.J., Peng, K.-W., and Bell, J.C. (2012). Oncolytic viro-therapy. Nat. Biotechnol. 30, 658-670.
30. Saijyo, S., Kudo, T., Suzuki, M., et al. (1995). Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J. Exp. Med. 177, 61-71.
31. Schwarz, A.J. (1962). Preliminary tests of a highly attenuated measles vaccine. Am. J. Dis. Child. 103, 386-389.
32. Seo, E., Abei, M., Wakayama, M., et al. (2005). Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res. 65, 546-552.
33. Sia, K.C., Huynh, H., Chinnasamy, N., et al. (2012). Suicidal gene therapy in the effective control of primary human hepatocel-lular carcinoma as monitored by noninvasive bioimaging. Gene Ther. 19, 532-542.
34. Sioka, C., and Kyritsis, A.P. (2009). Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol. 63, 761-767.
35. Skehan, P., Storeng, R., Scudiero, D., et al. (1990). New colori-metric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
36. Skipworth, J.R.A., Olde Damink, S.W.M., Imber, C., et al. (2011). Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol. Ther. 34, 1063-1078.
37. Stackhouse, M.A., Pederson, L.C., Grizzle, W.E., et al. (2000). Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther. 7, 1019-1026.
38. Tomayko, M.M., and Reynolds, C.P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154.
39. Ungerechts, G., Frenzke, M.E., Yaiw, K.-C., et al. (2010). Mantle cell lymphoma salvage regimen: synergy between a repro-grammed oncolytic virus and two chemotherapeutics. Gene Ther. 17, 1506-1516.
40. Ungerechts, G., Springfeld, C., Frenzke, M.E., et al. (2007a). Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res. 67, 10939-10947.
41. Ungerechts, G., Springfeld, C., Frenzke, M.E., et al. (2007b). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 15, 1991-1997.
42. Völker, I., Bach, P., Coulibaly, C., et al. (2013). Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques. Hum. Gene Ther. Clin. Dev. 24, 11-22.
43. Wildner, O., Morris, J.C., Vahanian, N.N., et al. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57-62.
44. Yamada, S., Kuroda, T., Fuchs, B.C., et al. (2012). Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther. 19, 160-170.
45. You, M.-H., Kim, W.-J., Shim, W., et al. (2009). Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. J. Gas-troenterol. Hepatol. 24, 1393-1400.
46. Zaoui, K., Bossow, S., Grossardt, C., et al. (2012). Chemovir-otherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther. 19, 181-191.
47. Zhu, Z.B., Chen, Y., Makhija, S.K., et al. (2006). Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int. J. Oncol. 29, 1319-1329.